Tracking chip technology developer Bluechiip (ASX:BCT) has forged a strategic partnership with US CRO Gentris Corporation. Bluechiip has agreed to provide Gentris with its eponymous temperature sensing and tracking chips, which are initially being developed for cryogenic sample management. [ + ]

Alchemia (ASX:ACL) has filed papers with ASIC regarding the proposed spin-off of its oncology business, after the independent analysts hired to assess the deal concluded that the demerger is in shareholders' best interests. [ + ]

Sirtex Medical (ASX:SRX) increased its FY12 profit by 49%, on the back of strong sales of its SIR-Spheres targeted radiation therapy treatments for liver cancer. [ + ]

Rather than trying to kill bacteria outright with drugs, Université de Montréal researchers have discovered a way to disarm bacteria that may allow the body’s own defence mechanisms to destroy them. [ + ]

Nexgen - an anti-viral technology for plants developed at The University of Queensland (UQ) - has attracted a $50,000 Skills and Knowledge grant from Commercialisation Australia (CA). [ + ]

Plans are now progressing for the implementation of quarterly payments of the R&D Tax Incentive, to be accessible for each quarter commencing on or after 1 January 2014. In preparations, the Assistant Treasurer, the Hon David Bradbury and the Minister for Industry and Innovation, the Hon Greg Combet, have jointly released a public consultation paper on the design and implementation of the R&D quarterly credits. [ + ]

Strong early sales of Nanosonics' (ASX:NAN) disinfection cabinets helped the company triple its revenue and cut its full-year losses by 58% in FY12. [ + ]

Start-up MiReven has received a $500,000 funding injection, after forging R&D partnerships and reaching internal milestones in efforts to develop cancer treatments based on a strain of microRNA. [ + ]

Calzada (ASX:CZD) has been forced to push back the planned completion date for a planned human clinical trial of its NovoSorb BTM burns treatment product until well into 2013. [ + ]

Alchemia (ASX:ACL) has reached two new milestones in its efforts to spin off its oncology business into a separate company listed on the Nasdaq. [ + ]

Patrys (ASX:PAB) ended FY12 in a more stable financial position, after raising enough cash to see it through until early 2014. [ + ]

AusBiotech invites members’ comments on the recently released Business Tax Working Group (BTWG) discussion paper, which includes amongst its issues for discussion four options that seek to limit the R&D Tax Incentive to companies with turnover over $20 million. [ + ]

The US FDA has provisionally cleared GI Dynamics (ASX:GID) to jump straight to a full clinical trial of EndoBarrier to treat Type 2 diabetes patients who are obese. [ + ]

The National Acoustic Laboratories, the Hearing CRC and the ABC have teamed up as part of National Science Week to run Sound Check Australia, the national noise and hearing survey, and are giving participants a chance to win $1000 worth of concert tickets. [ + ]

Mesoblast (ASX:MSB) has reinvested a sizeable chunk of the revenues from its licensing deal with Cephalon into boosting research and development efforts for its adult stem cell technology, bumping up total expenses by more than $58 million in FY12. [ + ]